Ruediger NaumannEtienne - Encision Independent Director

ECIADelisted Stock  USD 0.46  0.00  0.00%   

Director

Dr. Ruediger NaumannEtienne, Ph.D., serves as an Independent Director of Encision Inc., since October 2008. Mr. NaumannEtienne was the General Partner of Intertec Healthcare Partners, a fund investing in medical companies, since 2006. Since 1989, he has also been the owner and Managing Director of Intertec Group, an investment company specializing in the medical technology field. Intertec Group has implemented growth strategies for OEC Medical Systems, Laserscope, Quinton Instruments and Cardiac Science. From 2006 through 2010, he was Chairman of Cardiac Science having previously served as the Chairman of a predecessor company, Quinton Instruments, from 2000 to 2005. He was also CEO of Quinton Instruments from 2000 to 2003. From 1993 until 1996, he was Chairman of OEC Medical Systems and CEO of the same company from 1995 to 1997 since 2008.
Age 71
Tenure 16 years
Phone303 444 2600
Webhttps://www.encision.com
NaumannEtienne is also a director of Varian Medical Systems and IRIDEX Corporationrationrationration.

Encision Management Efficiency

The company has return on total asset (ROA) of (0.0831) % which means that it has lost $0.0831 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2203) %, meaning that it created substantial loss on money invested by shareholders. Encision's management efficiency ratios could be used to measure how well Encision manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 206 K in liabilities with Debt to Equity (D/E) ratio of 0.35, which is about average as compared to similar companies. Encision has a current ratio of 3.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Encision until it has trouble settling it off, either with new capital or with free cash flow. So, Encision's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Encision sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Encision to invest in growth at high rates of return. When we think about Encision's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Richard CarucciKontoor Brands
61
Olivia KirtleyBarrick Gold Corp
66
Michael JesselsonAmerican Eagle Outfitters
63
JeanMarc HuetCanada Goose Holdings
51
Mark HippCarters
58
Loreto SilvaBarrick Gold Corp
55
Bruce CleverlyCarters
69
Giuseppina BuonfantinoCarters
52
David PulverCarters
78
Graham ClowBarrick Gold Corp
66
Pablo MarcetBarrick Gold Corp
53
Andrew QuinnBarrick Gold Corp
66
Hali BorensteinCarters
35
Jodi ButtsCanada Goose Holdings
48
Janice PageAmerican Eagle Outfitters
71
Joshua BekensteinCanada Goose Holdings
61
Gretchen PriceCarters
64
Noel SpiegelAmerican Eagle Outfitters
72
Karl VoltaireBarrick Gold Corp
63
Maureen ChiquetCanada Goose Holdings
57
Thomas WhiddonCarters
66
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado. Encision operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 31 people. Encision [ECIA] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Encision is listed under Medical Equipment category by Fama And French industry classification.

Management Performance

Encision Leadership Team

Elected by the shareholders, the Encision's board of directors comprises two types of representatives: Encision inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Encision. The board's role is to monitor Encision's management team and ensure that shareholders' interests are well served. Encision's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Encision's outside directors are responsible for providing unbiased perspectives on the board's policies.
Brad Greathouse, Vice President - Regulatory Affairs & Quality Assurance
Michael Biggs, VP of Engineering
Peter Geary, Vice President - Operations
Mala Ray, Controller, Treasurer and Corporate Secretary
Gregory Trudel, CEO and President and Director
Valerie Ray, VP of Operations
Brian Jackman, VP Marketing
Robert Fries, Independent Director
Ruediger NaumannEtienne, Independent Director
Patrick Pace, Executive Chairman of the Board
David Newton, Co-Founder, VP of Technology and Director
Vern Kornelsen, Independent Director

Encision Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Encision a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Encision

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Encision position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Encision will appreciate offsetting losses from the drop in the long position's value.

Moving against Encision Pink Sheet

  0.56NEPH NephrosPairCorr
  0.53MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.5NVST Envista Holdings Corp Financial Report 1st of May 2024 PairCorr
The ability to find closely correlated positions to Encision could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Encision when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Encision - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Encision to buy it.
The correlation of Encision is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Encision moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Encision moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Encision can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Consideration for investing in Encision Pink Sheet

If you are still planning to invest in Encision check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Encision's history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio